Leydig-cell-tumors|OMICS International|Journal Of Obesity And Weight Loss Therapy

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.


Leydig cell tumor is a model that resembles human cachexia rather well, because the tumor induced slow progression of anorexia, as well as marked weight loss. The Leydig cell tumors produce TNF and that TNF induces cachexia. Therefore, LPL activator NO-1886 administered to Leydig cell tumor-bearing rats may have beneficial effects. When Leydig cells were inoculated into rats, there was an early decrease in plasma total protein and albumin levels after inoculation, followed by a decrease in plasma glucose and HDL-C, with the animals showing signs of malnutrition throughout. Food consumption decreased after tumor inoculation, and thereafter the rats rapidly grew leaner. LPL activity in rat adipose tissue and adipose tissue weight were decreased by Leydig cell inoculation. NO-1886 prevented the decrease in carcass weight and malnutrition resulting from the appetite suppression attributable to Leydig cell tumors. From these results, the LPL activator is considered to be potentially beneficial for the treatment of cancer cachexia and other wasting syndromes Peer review refers to the work done during the screening of submitted manuscripts and funding applications. This process encourages authors to meet the accepted standards of their discipline and reduces the dissemination of irrelevant findings, unwarranted claims, unacceptable interpretations, and personal views. Publications that have not undergone peer review are likely to be regarded with suspicion by academic scholars and professionals.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on June, 2021